ARTICLE | Product Development
Amgen to accelerate China strategy via BeiGene deal
BeiGene deal allows Amgen to parallel-track China commercialization of oncology and non-onc portfolios
November 9, 2019 12:39 AM UTC
Updated on Feb 14, 2020 at 6:58 PM UTC
Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew.
Through the deal with BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), announced Oct. 31, Amgen Inc. (NASDAQ:AMGN) can launch a two-pronged strategy in China that advances its oncology and non-oncology programs in parallel, without overextending...